A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia

NCT05458128 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Hypersomnia
Excessive Daytime Sleepiness

Interventions

DRUG: Pitolisant

Sponsor

Harmony Biosciences Management, Inc.